Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR... see more

Bullboard (TSX:OPS)

View:
Post by retiredcfon Nov 29, 2022 9:43am

Only a Matter of Time

Before Savvywire is used throughout the world. Put this one away, relax and come back in a couple of years with a big smile on your face. All IMHO of course. GLTA The launch in New Zealand  ...more  
Post by Nadia6519on Nov 27, 2022 9:18am

This morning's La Presse _ Richard Dufour

Positive sentiment in spite of tweak in rating from Raymond James (my comment). Opsens fait toujours l’unanimit sur Bay Street, mais un analyste a ajust sa recommandation mardi aprs que l ...more  
Post by retiredcfon Nov 25, 2022 10:20am

Stifel

Bargain basement price this morning. GLTA 09:18 AM EST, 11/25/2022 (MT Newswires) -- Stifel GMP on Friday reiterated its buy rating on the shares of Opsens (OPS.TO) and its C$3.75 price target ...more  
Comment by ddogoldon Nov 25, 2022 10:12am

RE:Hang on from. Raymond James see Opsens trimmed at $ 5,00

Still holding but a smaller position . Still believe a buyout is our best option to maximize our products . Glta
Comment by GoldenArmon Nov 25, 2022 9:04am

RE:RE:Paradigm Capital...

Keep an eye out fr Board additions. These will be the people that smooth out stuff before takeover by a big company.
Comment by Qccity1on Nov 24, 2022 1:01pm

RE:Paradigm Capital...

Maybe sharing the link will be better... OpSens is a takeout target, says Paradigm Capital - Cantech Letter
Post by Qccity1on Nov 24, 2022 12:59pm

Paradigm Capital...

OpSens is a takeout target, says Paradigm Capital Paradigm Capital analyst Scott McAuley still likes the look of Canadian medical device maker OpSens Inc ...more  
Post by Nadia6519on Nov 23, 2022 11:26am

Excellent coverage

In my humble opinion, the European market potential is currently being somewhat ignored.  Once that part of the world starts moving, we should see interesting things. GLTA
Post by retiredcfon Nov 23, 2022 10:00am

RBC 2

Their upside scenario target also remains at $5.00. GLTA November 22, 2022 Opsens Inc. FQ4/22: Revenues slightly below estimates; Positive early feedback on ...more  
Post by bossuon Nov 23, 2022 8:49am

Hang on from. Raymond James see Opsens trimmed at $ 5,00

Investors have to be patient ! Despite continuing to have “strong conviction” on the potential for its SavvyWire product as it continues to gain traction on both sides of the border, Raymond ...more  
Comment by Possibleidiot01on Nov 22, 2022 2:57pm

RE:RE:If I understand well...

Follow where the money went . Operating expenses for FY 2022 were $28.8 million compared with $19.6 million for FY 2021. The increase in operating expenses is primarily due to increased headcount ...more  
Comment by retiredcfon Nov 22, 2022 10:50am

RE:If I understand well...

Good to see a voice of reason. We may close the day in the green depending on how well the conference call goes. GLTA
Post by Nadia6519on Nov 22, 2022 10:20am

If I understand well...

... The increased loss is primarily due to higher operating expenses to drive growth in coronary products and preparation of the large-scale launch of SavvyWire for TAVR (Transcatheter Aortic ...more  
Comment by retiredcfon Nov 22, 2022 9:55am

RE:RE:Q4 2022 revenues lower than Q3 2022

When people like this show up (with a total of 4 posts on SH), you know it's time to buy. GLTA
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities